MIRA
INFORM REPORT
|
Report Date : |
16th
February, 2007 |
IDENTIFICATION
DETAILS
|
Name : |
YES
PHARMA LTD. |
|
|
|
|
Registered Office : |
P.O. Box 11075, Sofri House No.
33, Har Tov Industrial Zone , Beit Shemesh 99100 Israel |
|
|
|
|
Country : |
Israel |
|
|
|
|
Date of Incorporation : |
17.01.2005 |
|
|
|
|
Com. Reg. No.: |
51-363979-9 |
|
|
|
|
Legal Form : |
Private
Limited Company |
|
|
|
|
Line of Business : |
Agencies in the field of raw
materials for the pharmaceutical branch & Also international traders in
raw materials for the pharmaceutical field. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually
Correct |
|
|
|
|
Litigation : |
Clear |
Company Name & Address
YES PHARMA LTD.
Telephone 972 2 992 99 33
Fax 972 2 992 99 55
P.O. Box 11075
Sofri House No. 33
Har Tov Industrial Zone
BEIT
SHEMESH 99100 ISRAEL
HISTORY
A private limited company,
incorporated as such as per file No. 51-363979-9 on the 17.1.2005.
SHARE CAPITAL
Authorized share capital NIS
10,000.00, divided into - 1,000,000 ordinary shares of NIS 0.01 each, of which
shares amounting to NIS 100.00 were issued.
SHAREHOLDERS
Subject is fully owned by Gideon
Schurder.
SOLE DIRECTOR AND GENERAL MANAGER
Gideon Schurder.
BUSINESS
Agencies in the field of raw materials for
the pharmaceutical branch.
Also international traders in raw materials
for the pharmaceutical field.
All sales are on a commission basis.
All of subject suppliers are foreign.
Among subject’s customers: TEVA
PHARMACEUTICALS, DEXXON, TARO PHARMACEUTICAL INDUSTRIES, CHEMAGIS, CTS CHEMICAL
INDS., etc.
Sole local agents of:
CIPLA, NICHOLAS PIRAML, INDSWIFT, BENZOCHEM,
all of India,
STEROID, of Italy,
CRYSTAL PHARMA, of Spain.
Operating from rented premises, on an area
of 160 sq. meters, in the Har Tov Industrial Zone, Beit Shemesh.
Having 9 employees (had 5 in the beginning
of 2006).
MEANS
Holding no stocks, work is based
on orders.
Financial data not forthcoming.
There is 1 charge for unlimited amount
registered on the company assets, in favor of Bank Hapoalim Ltd.
ANNUAL SALES
Actual revenues derive from
commission on sales.
2005 sales volume claimed to be
US$ 2,500,000, of which US$ 1,500,000 for exports.
2006 sales volume claimed to be
US$ 4,500,000, of which US$ 1,250,000 for exports.
BANKERS
Bank Hapoalim Ltd., Beit Shemesh
Branch (No.692), account No. 531386.
A check with the Central Banks'
database did not reveal anything detrimental on subject’s a/m account.
CHARACTER AND REPUTATION
Nothing unfavorable learned.
According to the Industrials Association,
sales of the pharmaceutical sector reached US$ 3.1 billion in 2005, a 29%
increase from 2004. Sales to the local market were US$ 600 million, same as in
2004, and exports were US$ 2.5 billion, 40% increase from 2004.
In the first 3 quarters of 2006, exports
were US$ 2.27 billion (50% increase compared to the parallel period in 2005).
Most exports (72%) are to the USA and 13% to the EU.
The
pharmaceutical market is considered stable and payment morality is good.
SUMMARY
Good for trade engagements.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|